Your SlideShare is downloading. ×
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
non-hodgkin’s-lymphoma
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

non-hodgkin’s-lymphoma

740

Published on

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
740
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
21
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Non-Hodgkin’s Lymphoma 5th ASH Refresher Course Tanin Intragumtornchai, M.D.
  • 2. Special Problems in B-Cell Lymphomas • Burkitt lymphoma in adults Perkins AS, Friedberg JW, Rochestor U, NY • Primary mediastinal B-cell lymphoma Johnson PWM, Davies AJ, U Southampton, UK • Marginal zone lymphomas Kahl B, Yang D, U Wisconsin
  • 3. Burkitt Lymphoma: Diagnostic Features • High rate of proliferation (Ki-67 > 95%) • Activation of MYC gene at 8q24 (Giemsa banding or FISH) • Relative simplicity of karyotype • No cleaves or folds in nuclear contour • Lack of Tdt positivity
  • 4. Key Clinical Features • Bulky abdominal mass, B symptoms, laboratory evidence of tumor lysis • 70% bone marrow involvement • 40% leptomeningeal involvement
  • 5. Treatment • Intensive, short duration chemotherapy (high-dose alkylating agents, CNS prophylaxis) • ALL-like regimen • Therapy included consolidation with auto- SCT
  • 6. OS According to Age All cases > 40 yrs • CODOX-M/IVAC 71% 39% • ALL-like 51% 40% • Hyper-CVAD 57% 17% (> 60 yrs) 89% (rituximab- based)
  • 7. Conclusion • A highly curable malignancy • Inferior outcome in patients age > 40 years • Important to differentiate from “atypical Burkitt”
  • 8. Primary Mediastinal B-Cell Lymphoma • Median age 37 years • Stage I/II 74% • Elevated LDH 77% • Bulk (>10 cm) 75% • Pleural or pericardial 50% effusion
  • 9. Treatment • Role of third generation regimen • Role of rituximab • Consolidating radiotherapy • How to evaluate residual mass? • Role of HDT
  • 10. Role of Third Generation Regimen • Three large retrospective (one population- based) studies showed superior OS for MACOP-B, VACOP-B compared to CHOP (70% vs 50%, p < 0.05)
  • 11. Role of Rituximab • Addition of rituximab to dose-adjusted EPOCH (n = 44) was associated with favorable EFS and OS (87% and 93%, p < 0.05) • Retrospective population-based study did not showed superiority of R-CHOP over 3rd generation regimen
  • 12. Consolidating Radiotherapy • Mediastinal radiotherapy is essential in patients achieving PR after initial chemotherapy (increased CR rate from 42% to 95%) • Role in patients with CR is questionable in particular those treated with rituximab- based regimen
  • 13. How to Evaluate Residual Mass? • FDG-PET is the tool of choice • All patients with positive PET relapsed compared to 26% in patients with negative PET • Gallium scan is less expensive but time- consuming and low spatial resolution
  • 14. Role of HDT • No role in patients with first CR • In chemosensitive relapse and refractory disease, the long-term OS were 40-70% and 50-60%, respectively
  • 15. Nodal MZL • Median age 60 years • Male : female 1:1 • Present in advanced stage with non-bulky widespread lymphadenopathy • 1/3 had bone marrow involvement
  • 16. Nodal MZL • Clinical course resembled other nodal indolent lymphomas • Prognosis less favourable compared to MALT, splenic MZL and FL. Roughly comparable to SLL. • 16% transformed to large-cell in 4.5 years • Apply same treatment approach as FL
  • 17. Splenic MZL • Present with moderate to massive splenomegaly • Cytopenias due to splenic sequestration (main factor) and marrow involvement • Best diagnostic tool is bone marrow examination • Differentiate with HCL by showing negative staining to CD25 and CD103
  • 18. Splenic MZL • Splenectomy is the treatment of choice • In asymptomatic patients using watch and wait policy, median time to treatment is 3 years • Systemic chemotherapy (favored purine analogues) is indicated in patients contraindication to splenectomy or had heavy burden of disease outside spleen
  • 19. Splenic MZL • 5-year OS 76% • Three adverse poor prognostic factors: hemoglobin < 12 g/dl, serum albumin < 3.5 g/dl and LDH > ULN
  • 20. Gastric MALT Lymphomas • Comprised 30% of all MALT lymphomas • Endoscopy showed erythema, erosions, ulceration. Masses are uncommon. • Establish H. pylori status is essential (histologic examination, biopsy urease test, urea breath test, stool antigen test and selorogy). • 90% of patients had H. pylori infection • t(11;18) evaluation by FISH
  • 21. Treatment • 75% of stage IE patients with H. pylori infection and without t(11;18) will respond to H. pylori eradication • Response is quite slow. Complete response is established in one year. • Repeat endoscopy every 3-6 months until normalization of gastric mucosa then annually • Routine biopsy of normal appearing mucosa is not recommended
  • 22. Treatment • Low-dose radiotherapy is indicated in patients with H-pylori negative or failure to H. pylori eradication (100% OS) • Patients with advanced disease were treated with the same principle as patients with advanced stage FL
  • 23. Non-gastric MALT Lymphomas • Comprised 70% of all MALT lymphomas • Association with infectious agents - B burgdorfi: cutaneous MALT lymphoma - C psittaci: conjunctival MALT lymphoma - C jejuni: IPSID • Frequency of associations and role of antimicrobial therapy are still under investigations
  • 24. Treatment • Low-dose radiotherapy is the treatment of choice • 5-year OS > 90% and 10-year OS > 80%
  • 25. Peripheral T-Cell Lymphomas • Prognosis and 1ry therapy in PTCL Kerry J Savage (BC Cancer Agency)
  • 26. Addition of Etoposide to CHOP/CHOP- Like Regimen • CHOEP vs CHOP : EFS 71% vs 50% (p =.01)(GNHLG) • VIP/ABVD vs CHOP : no difference in OS and EFS (GOELAMS)
  • 27. Subtype-Specific Therapies • Cutaneous ALCL: local excision with or without radiotherapy • ALK pos ALCL : CHOP • Localized NK/T lymphoma, nasal type: - primary radiotherapy is the principal treatment. Chemotherapy provide additional benefit? - Initial RT vs initial CT : CR 83% vs 20% (Li et al, JCO 2006)
  • 28. Conclusions • Outcome is unsatisfactory with CHOP • Therapies should be tailored according to the subtypes • Large well-designed RCTs coorporating novel therapies are urgently needed.
  • 29. WHO 2008 B-Cell Lymphomas (New Addition) • Primary cutaneous follicle center cell lymphoma • DLBCL, NOS - T-cell/histiocyte rich large B-cell lymphoma - Primary DLBCL of CNS - Primary cutaneous DLBCL, leg type • DLBCL of chronic inflammation • ALK-pos large B-cell lymphoma • Plasmablastic lymphoma • Large B-cell lymphoma associated with Castleman disease • B-cell lymphoma, intermediate beteween DLBCL and BL • B-cell lymphoma, intermediate beteween DLBCL and HL
  • 30. WHO 2008 T-Cell Lymphomas (New Addition) • Systemic EBV positive-T-cell lymphoproliferative diseases of childhood • Hydroa vacciniiforme-like lymphoma • Primary cutaneous CD30 positive T-cell lymphoproliferative disorders - lymphomatoid papulosis - primary cutaneous ALCL • Primary cutaneous gamma-delta T-cell lymphoma • ALCL, ALK pos
  • 31. DLBCL of Chronic Inflammation • Long standing chronic inflammation • Associated with EBV infection • Involve narrow space, body cavities • Prototype : pyothorax-ass-lymphoma. • Poor pg, 5-yr OS 25-30%
  • 32. Hydroa Vacciniiforme-Like Lymphoma • Children/adolescence of Asian, Native Americans, South Americans • Associated with EBV • Associated with insect bites, sun sensitivity
  • 33. Lymphomatoid Papulosis • Chronic relapsing papular, papulonecrotic and/or nodular skin lesions. • Good prognosis

×